Inhibition of salivary glands to reduce uptake and toxicity of PSMA-ligands

Inhibition of salivary glands to reduce uptake and toxicity of PSMA-ligands - Inhibition of Salivary Glands

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON46014

Enrollment

Registered

2018-05-24

Start date

2018-05-24

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

accumulation in salivary glands. Biodistribution of PSMA-ligands

Interventions

Intravenous administration of the investigational product GPB.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Received PSMA PET/CT on clinical indication (1cm.

Exclusion criteria

Exclusion criteria: - Poor quality of the baseline PSMA PET/CT scan - Planned start or changes in treatment prior to study procedures. - Age

Design outcomes

Primary

Measure	Time frame
The total uptake of Ga-PSMA on PET/CT in all macroscopic salivary glands together (and its relative decrease after inhibition with GPB).	—

Secondary

Measure	Time frame
The total perfusion signal on ASL MR in representative thick slices of the parotid and submandibular glands together (and its relative decrease after inhibition with GPB).	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)